Plasma ubiquinone to ubiquinol ratio in patients with hepatitis, cirrhosis, and hepatoma, and in patients treated with percutaneous transluminal coronary reperfusion
Affiliations: Research Center for Advanced Science and Technology, University of Tokyo, 4‐6‐1 Komaba, Meguro‐ku, Tokyo 153‐8904, Japan
Note: [] To whom correspondence should be addressed.
Abstract: To assess the degree of oxidative stress, we measured plasma ubiquinone‐10 percentage (%CoQ‐10) in total amounts of ubiquinone‐10 in patients with chronic active hepatitis, liver cirrhosis, and hepatocellular carcinoma, and in age‐matched control subjects. %CoQ‐10 values were 12.9 \pm 10.3 (n={}28), 10.6 \pm 6.8 (n={}28), 18.9 \pm 11.1 (n={}20), and 6.4 \pm 3.3 (n={}16), respectively, showing a significant increase in oxidative stress in patient groups as compared to control subjects. There were no differences in total amounts of ubiquinone‐10 and ubiquinol‐10 among the four groups. We next measured %CoQ‐10 in plasmas obtained from nine patients treated with percutaneous transluminal coronary angioplasty (PTCA). Plasmas were collected when hospitalized, and at the time (0, 4, 8, 12, 16, and 20 hr, and 1, 2, 3, 4, and 7 days) after the PTCA. %CoQ‐10 values before and right after PTCA were 9.9 \pm 2.8 and 11.4 \pm 2.0, respectively, reached a maximum (20–45) at 1 or 2 days later, and decreased to 7.9 \pm 2.7 at 7 days after PTCA, indicating an increase in oxidative stress in patients during coronary reperfusion.
